CMV after hematopoietic stem cell transplantation: Difference between revisions

From IDWiki
m (Text replacement - "Clinical Presentation" to "Clinical Manifestations")
No edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
−
== Clinical Manifestations ==
 +
== Background ==
⚫
* With monitoring and preemptive therapy, CMV pneumonitis has decreased to 5% of seropositive allogeneic recipients
  
⚫
* [[Pneumonitis]] (63%)
  
⚫
* [[Enteritis]] (26%)
  
⚫
* [[Retinitis]] (5%)
  
   
  +
* Reactivation of latent recipient [[CMV]] infection is common after [[hematopoietic stem cell transplantation]]
⚫
== Management ==
  
  +
⚫
=== Preemptive therapy ===
  
  +
=== Microbiology ===
⚫
* Most frequently managed with weekly viral loads and preemptive treatment (PET) at a lab-specific threshold
  
  +
−
* Antiviral treatment:
  
  +
* Refer to [[Cytomegalovirus#Microbiology|Cytomegalovirus]]
−
** [[Is treated by::ganciclovir]] 5 mg/kg q12h for 7 to 14 days (induction) followed by [[Is treated by::valganciclovir]] 900 mg po daily (maintenance) until a few weeks after viremia resolves
  
  +
⚫
** If concerns about oral antiviral, would continue [[Is treated by::ganciclovir]] 5 mg/kg IV daily (maintenance)
  
  +
=== Epidemiology ===
⚫
** If ganciclovir resistance or bone marrow suppression, next step is [[Is treated by::foscarnet]] 90 mg/kg IV q12h (induction) followed by q24h (maintenance)
  
  +
⚫
* Use CMV safe (leukoreduced or filtered) blood products if the recipient is CMV seronegative
  
  +
* Reactivates in 60 to 70% of CMV-seropositive patients and primary infection affects 20 to 30% of seronegative recipients who have seropositive donors
  +
  +
{| class="wikitable"
  +
!Donor
  +
!Recipient
  +
!Risk
  +
|-
  +
|±
  +
| +
  +
|60-70%
  +
|-
  +
| +
  +
|–
  +
|20-30%
  +
|-
  +
|–
  +
|–
  +
|5%
  +
|}
  +
  +
* Risk is proportional to the amount of T cell dysfunction, so risk is higher earlier in disease and after [[fludarabine]], [[alemtuzumab]], or [[2-chlorodeoxyadenose]]
  +
* GVHD is another important risk factor
  +
  +
==Clinical Manifestations==
  +
  ⚫
*With monitoring and preemptive therapy, CMV pneumonitis has decreased to 5% of seropositive allogeneic recipients
  ⚫
*[[Pneumonitis]] (63%)
  ⚫
*[[Enteritis]] (26%)
  ⚫
*[[Retinitis]] (5%)
  +
*Increased risk of rejection
  +
  ⚫
==Management==
  +
  +
=== Prophylaxis ===
  +
  +
* Now commonly done with [[letermovir]], started within 28 days of transplantation
  +
  ⚫
===Preemptive Therapy===
  +
  ⚫
*Most frequently managed with weekly viral loads and preemptive treatment (PET) at a lab-specific threshold
  +
*Antiviral treatment follows a model of induction therapy for 14 days; if it has declined by at least 1 log, then step down to lower-dose maintenance therapy until viremia resolves fully; otherwise, continue induction dosing
  +
**Induction therapy
  +
***[[Is treated by::Ganciclovir]] 5 mg/kg q12h
  ⚫
***If concerns about resistance or bone marrow suppression, [[Is treated by::foscarnet]] 90 mg/kg IV q12h
  +
**Maintenance therapy
  +
***[[Is treated by::Valganciclovir]] 900 mg po daily
  ⚫
***If concerns about oral absorption, continue [[Is treated by::ganciclovir]] 5 mg/kg IV q24h
  +
***If concerns about resistance or bone marrow suppression, [[Is treated by::foscarnet]] 90 mg/kg IV q24h
  ⚫
*Use CMV safe (leukoreduced or filtered) blood products if the recipient is CMV seronegative
   
 
{| class="wikitable sortable"
  
{| class="wikitable sortable"
−
! Serostatus
 +
!Serostatus
−
! Blood products
 +
!Blood products
−
! Duration of PET
 +
!Duration of PET
 
|-
  
|-
−
| D-/R-
 +
|D-/R-
−
| CMV safe
 +
|CMV safe
−
| weeks 2 to 12
 +
|weeks 2 to 12
 
|-
  
|-
−
| D+/R-
 +
|D+/R-
−
| CMV safe
 +
|CMV safe
−
| weeks 2 to 12
 +
|weeks 2 to 12
 
|-
  
|-
−
| autologous R-
 +
|autologous R-
−
| CMV safe
 +
|CMV safe
−
| weeks 2 to 5
 +
|weeks 2 to 5
 
|-
  
|-
−
| D±/R+
 +
|D±/R+
−
| CMV untested
 +
|CMV untested
−
| weeks 2 to 12, then q2-4wk until week 26
 +
|weeks 2 to 12, then q2-4wk until week 26
 
|-
  
|-
−
| autologous R+
 +
|autologous R+
−
| CMV untested
 +
|CMV untested
−
| weeks 2 to 5
 +
|weeks 2 to 5
 
|}
  
|}
   
−
=== CMV disease ===
 +
===CMV Disease===
  +
−
* Treatment is with [[Is treated by::ganciclovir]] induction for 14 to 21 days with IVIG 500 mg/kg every other day, followed by maintenance [[ganciclovir]] for at least 3 to 4 weeks
 +
*Treatment is with [[Is treated by::ganciclovir]] induction for 14 to 21 days with IVIG 500 mg/kg every other day, followed by maintenance [[ganciclovir]] for at least 3 to 4 weeks
−
* May need to continue maintenance for longer if patient has [[GVHD]], enteritis with deep ulcerations, or retinitis
 +
*May need to continue maintenance for longer if patient has [[GVHD]], enteritis with deep ulcerations, or retinitis
   
 
[[Category:Immunocompromised hosts]]
  
[[Category:Immunocompromised hosts]]

Latest revision as of 17:21, 19 September 2020

Background

Microbiology

Epidemiology

  • Reactivates in 60 to 70% of CMV-seropositive patients and primary infection affects 20 to 30% of seronegative recipients who have seropositive donors
Donor Recipient Risk
± + 60-70%
+ – 20-30%
– – 5%

Clinical Manifestations

  • With monitoring and preemptive therapy, CMV pneumonitis has decreased to 5% of seropositive allogeneic recipients
  • Pneumonitis (63%)
  • Enteritis (26%)
  • Retinitis (5%)
  • Increased risk of rejection

Management

Prophylaxis

  • Now commonly done with letermovir, started within 28 days of transplantation

Preemptive Therapy

  • Most frequently managed with weekly viral loads and preemptive treatment (PET) at a lab-specific threshold
  • Antiviral treatment follows a model of induction therapy for 14 days; if it has declined by at least 1 log, then step down to lower-dose maintenance therapy until viremia resolves fully; otherwise, continue induction dosing
    • Induction therapy
      • Ganciclovir 5 mg/kg q12h
      • If concerns about resistance or bone marrow suppression, foscarnet 90 mg/kg IV q12h
    • Maintenance therapy
      • Valganciclovir 900 mg po daily
      • If concerns about oral absorption, continue ganciclovir 5 mg/kg IV q24h
      • If concerns about resistance or bone marrow suppression, foscarnet 90 mg/kg IV q24h
  • Use CMV safe (leukoreduced or filtered) blood products if the recipient is CMV seronegative
Serostatus Blood products Duration of PET
D-/R- CMV safe weeks 2 to 12
D+/R- CMV safe weeks 2 to 12
autologous R- CMV safe weeks 2 to 5
D±/R+ CMV untested weeks 2 to 12, then q2-4wk until week 26
autologous R+ CMV untested weeks 2 to 5

CMV Disease

  • Treatment is with ganciclovir induction for 14 to 21 days with IVIG 500 mg/kg every other day, followed by maintenance ganciclovir for at least 3 to 4 weeks
  • May need to continue maintenance for longer if patient has GVHD, enteritis with deep ulcerations, or retinitis
Retrieved from "https://idwiki.org/index.php?title=CMV_after_hematopoietic_stem_cell_transplantation&oldid=6936"
Powered by MediaWiki
Powered by Semantic MediaWiki